ProCE Banner Activity

IMEA 055 FAST: BIC/FTC/TAF for Rapid Initiation of ART in Test-and-Treat Model

Slideset Download
Conference Coverage
In this small test-and-treat study, regimen was more than 80% effective at suppressing HIV-1 RNA at Week 24 with no treatment-emergent resistance seen in patients who did not achieve viral suppression; very low incidence of grade 3/4 or serious adverse events was seen.

Released: November 02, 2021

Expiration: November 01, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

ViiV Healthcare